ProCE Banner Activity

Tyrosine Kinase Inhibitors in Glioblastoma: Refining Precision Medicine

Multimedia
In this CME-certified, on-demand Webcast of a CCO symposium at SNO 2019, a panel of expert faculty reviews and discusses the latest data on the use of tyrosine kinase inhibitors for the treatment of glioblastoma.

Released: January 17, 2020

Expiration: January 15, 2021

No longer available for credit.

Share

Faculty

Tom Mikkelsen

Tom Mikkelsen, MD, FRCPC

Medical Director, Precision Medicine Program & Clinical Trials
Henry Ford Cancer Institute
Henry Ford Health System
Detroit, Michigan

Manmeet S. Ahluwalia

Manmeet S. Ahluwalia, MD, FACP

Professor, Department of Medicine
Clinic Lerner College of Medicine
Case Western Reserve Universtiy
Dean, Diane Miller Family Endowed Chair in Neuro-Oncology
Director, Brain Metastasis Research Program
Associate Director, Head of Operations
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center
Neurological Institute of Cleveland Clinic
Cleveland, Ohio

Rimas V. Lukas

Rimas V. Lukas, MD

Associate Professor of Neurology (Neuro-oncology)
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Learning Objectives

  • Integrate new targeted therapeutic TKIs into clinical practice for patients with glioblastoma multiforme based on individual patient and tumor characteristics
  • Describe the rationale for targeting NTRK gene fusion in glioblastoma and the effects of NTRK fusions on standard treatment selection
  • Discuss the current and emerging clinical data on promising small molecule TKI therapies for specific targets in the treatment recurrent glioblastoma multiforme
  • Select optimal treatment for patients with recurrent glioblastoma multiforme based on current evidence and molecular markers

Program Director Disclosure

Program Director

Tom Mikkelsen, MD, FRCPC

Medical Director, Precision Medicine Program & Clinical Trials
Henry Ford Cancer Institute
Henry Ford Health System
Detroit, Michigan

Tom Mikkelsen, MD, FRCPC, has no relevant financial relationships to disclose.

Faculty Disclosure

Primary Author

Manmeet S. Ahluwalia, MD, FACP

Professor, Department of Medicine
Clinic Lerner College of Medicine
Case Western Reserve Universtiy
Dean, Diane Miller Family Endowed Chair in Neuro-Oncology
Director, Brain Metastasis Research Program
Associate Director, Head of Operations
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center
Neurological Institute of Cleveland Clinic
Cleveland, Ohio

Manmeet S. Ahluwalia, MD, FACP, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bayer, Elsevier, Flatiron, Forma Therapeutics, Karyopharm, Prime Education, Tocagen, Varian Medical Systems, VBI Vaccines, and Wiley; has received funds for research support from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Incyte, Merck, Novocure, and Pharmacyclics; and has ownership interest (shareholder) from Doctible and Mimivax.

Rimas V. Lukas, MD

Associate Professor of Neurology (Neuro-oncology)
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Rimas V. Lukas, MD, has disclosed that he has received consulting fees from AbbVie and Monteris and other financial or material support from Bristol-Myers Squibb.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.